Investigation Overview
June 7, 2013 (Shareholders Foundation) - An investigation on behalf of current long-term stockholders of shares of TrovaGene Inc (NASDAQ:TROV) was announced concerning whether certain TrovaGene officers and directors possibly breached their fiduciary duties in connection with certain statements.
The investigation by a law firm concerns whether certain TrovaGene officers and directors breached their fiduciary duties in connection with their conduct in seeking shareholders approval for an amendment to the 2004 Stock Option Plan.
In the Proxy Statement filed by TrovaGene Inc with the Securities and Exchange Commissionthe Board of Directors recommends that TrovaGenes shareholders vote to approve an amendment to increase the number of shares issuable pursuant to the 2004 Stock Plan to 6,000,000 shares from 3,666,667 shares
According to the investigation the issuance of the additional shares could have a severe dilutive effect on the shares of NASDAQ:TROV common stock.
TrovaGene Inc reported that its annual Total Revenue declined from $0.27 million in 2010 to $0.26 million in 2011 and that its Net Loss declined from $5.45 million in 2010 to $2.24 million in 2011.
Shares of TrovaGene Inc (NASDAQ:TROV) grew from $2.16 per share in August 2012 to as high as $8.77 per share in January 2013.
On June 6, 2013, NASDAQ:TROV shares closed at $6.39 per share.